Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > July 7, 2025
Daily News
July 7, 2025
- Nxera Earns US$4.8 Million Milestone as Centessa’s OX2R Drug Advances
July 7, 2025
- Semaglutide, Tirzepatide, and More Drugs under PMDA Safety Review
July 7, 2025
- Japan’s Generic Use Rate Reaches 86.5% in FY2024: JGA
July 7, 2025
- Keytruda Tops Japan Drug Ranking for 21st Month: Encise
July 7, 2025
- Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
July 7, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…